The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The Impact of Hormone Replacement Therapy on Menopausal Symptoms in Younger High-Risk Women After Prophylactic Salpingo-Oophorectomy
Open accessAbstract
Purpose: Preventive health strategies for women at increased hereditary risk of ovarian cancer include gynecologic screening (GS) and/or prophylactic oophorectomy (PBSO). Hormone replacement therapy (HRT) is often prescribed to compensate for postsurgical endocrine deficiencies. This study examined the impact of HRT use on levels of endocrine symptoms and sexual functioning among premenopausal women who have undergone PBSO. Comparisons were made with similar women undergoing GS. Patients and Methods: Questionnaire data on endocrine symptoms and sexual functioning were obtained from 450 premenopausal, high-risk women who had participated in this nationwide, cross-sectional, observational study. Results: Thirty-six percent of women had undergone PBSO and 64% had opted for GS. In the PBSO group, 47% of the women were current HRT users. They reported significantly fewer vasomotor symptoms than nonusers (P < .05). However, compared with premenopausal women undergoing GS, oophorectomized HRT users were more likely to report vasomotor symptoms (P < .01). HRT users and nonusers reported comparable levels of sexual functioning. Compared with women in the GS group, oophorectomized HRT users reported significantly more sexual discomfort due to vaginal dryness and dyspareunia (P < .01). Conclusion: Although HRT has a positive impact on surgically induced vasomotor symptoms, it may be less effective than is often assumed. Symptom levels remain well above those of premenopausal women undergoing screening, and sexual discomfort is not alleviated by HRT. Physicians need to provide younger high-risk women considering PBSO with realistic information about both benefits and drawbacks of this preventive strategy, including information about premature menopause and HRT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431002 · Cited by 954
Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes
MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002978.pub2 · Cited by 543
Commonly Used Types of Postmenopausal Estrogen for Treatment of Hot Flashes: Scientific Review
Nelson, H. D. (2004) · JAMA · doi:10.1001/jama.291.13.1610 · Cited by 296 · cited 2×
“HRT has proven to be highly effective in alleviating vasomotor symptoms (eg, hot flushes, sweats) and urogenital atrophy in women undergoing natural menopause.(8,9) Because of its androgenic properties, tibolone has shown to have additional From the Division of Psychosocial”
BackgroundBöös, J. N., von Schoultz, B., & Carlström, K. (1993) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.3109/01674829309084451 · Cited by 188
Cited by
ESHRE Guideline: management of women with premature ovarian insufficiency
(2016) · Human Reproduction · doi:10.1093/humrep/dew027 · Cited by 1,555
Premature menopause or early menopause: Long-term health consequences
Shuster, L. T., Rhodes, D. J., Gostout, B. S., Grossardt, B. R., & Rocca, W. A. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.08.003 · Cited by 808
Vasen, H. F. A., Blanco, I., Aktan-Collan, K., Gopie, J. P., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., Burn, J., Capella, G., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-304356 · Cited by 746
Long-term health consequences of premature or early menopause and considerations for management
Faubion, S. S., Kuhle, C. L., Shuster, L. T., & Rocca, W. A. (2015) · Climacteric · doi:10.3109/13697137.2015.1020484 · Cited by 544
Ovarian Cancer Prevention and Screening
Menon, U., Karpinskyj, C., & Gentry-Maharaj, A. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002580 · Cited by 279
Cell Origins of High-Grade Serous Ovarian Cancer
Kim, J., Park, E., Kim, O., Schilder, J., Coffey, D., Cho, C.-H., & Bast, R. (2018) · Cancers · doi:10.3390/cancers10110433 · Cited by 264
Ishizuka, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.626924 · Cited by 262
HRT for women with premature ovarian insufficiency: a comprehensive review
Webber, L., Anderson, R. A., Davies, M., Janse, F., & Vermeulen, N. (2017) · Human Reproduction Open · doi:10.1093/hropen/hox007 · Cited by 141
“HRT significantly reduces vasomotor symptoms after prophylactic BSO (Madalinska et al., 2006) but does not significantly alter the reduction in breast cancer risk associated with BSO for BRCA1/2 mutation carriers, as compared to carriers without BSO or HRT (Armstrong et al., 2004; Rebbeck et al.,…”
BackgroundInfluentialAtema, V., van Leeuwen, M., Kieffer, J. M., Oldenburg, H. S. A., van Beurden, M., Gerritsma, M. A., Kuenen, M. A., Plaisier, P. W., Lopes Cardozo, A. M. F., van Riet, Y. E. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00655 · Cited by 105
Self-citationImpact of risk-reducing salpingo-oophorectomy in premenopausal women
Vermeulen, R. F. M., Beurden, M. V., Korse, C. M., & Kenter, G. G. (2017) · Climacteric · doi:10.1080/13697137.2017.1285879 · Cited by 62
van Driel, C., de Bock, G., Schroevers, M., & Mourits, M. (2019) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15471 · Cited by 33
Self-citationUse of hormone replacement therapy after risk‐reducing salpingo‐oophorectomy
Johansen, N., Liavaag, A. H., Iversen, O., Dørum, A., Braaten, T., & Michelsen, T. M. (2017) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.13120 · Cited by 23
Metadata
- Authors
- Madalinska, J. B., van Beurden, M., Bleiker, E. M. A., Valdimarsdottir, H. B., Hollenstein, J., Massuger, L. F., Gaarenstroom, K. N., Mourits, M. J. E., Verheijen, R. H. M., van Dorst, E. B. L., van der Putten, H., van der Velden, K., Boonstra, H., & Aaronson, N. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-08-01
- Volume
- 24
- Issue
- 22
- Pages
- 3576-3582
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108666051
- Cited by
- 214
- References
- 6
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.